CA2538759C - Substituted heterocyclic compounds as sirtuin inhitibitors - Google Patents

Substituted heterocyclic compounds as sirtuin inhitibitors Download PDF

Info

Publication number
CA2538759C
CA2538759C CA2538759A CA2538759A CA2538759C CA 2538759 C CA2538759 C CA 2538759C CA 2538759 A CA2538759 A CA 2538759A CA 2538759 A CA2538759 A CA 2538759A CA 2538759 C CA2538759 C CA 2538759C
Authority
CA
Canada
Prior art keywords
compound
disease
protein
sirt1
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2538759A
Other languages
English (en)
French (fr)
Other versions
CA2538759A1 (en
Inventor
Andrew Napper
Peter Distefano
Jeffrey Hixon
Thomas Mcdonagh
Jonathan M. Solomon
L. Julie Huber
Rory Curtis
Russell J. Thomas
Jean-Francois Pons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AOP Orphan IP AG
Original Assignee
Elixir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Pharmaceuticals Inc filed Critical Elixir Pharmaceuticals Inc
Publication of CA2538759A1 publication Critical patent/CA2538759A1/en
Application granted granted Critical
Publication of CA2538759C publication Critical patent/CA2538759C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CA2538759A 2003-09-12 2004-09-13 Substituted heterocyclic compounds as sirtuin inhitibitors Expired - Lifetime CA2538759C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US50281103P 2003-09-12 2003-09-12
US60/502,811 2003-09-12
US53144303P 2003-12-19 2003-12-19
US60/531,443 2003-12-19
US56050904P 2004-04-07 2004-04-07
US60/560,509 2004-04-07
PCT/US2004/029942 WO2005026112A2 (en) 2003-09-12 2004-09-13 Methods of treating a disorder

Publications (2)

Publication Number Publication Date
CA2538759A1 CA2538759A1 (en) 2005-03-24
CA2538759C true CA2538759C (en) 2015-11-03

Family

ID=34317479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2538759A Expired - Lifetime CA2538759C (en) 2003-09-12 2004-09-13 Substituted heterocyclic compounds as sirtuin inhitibitors

Country Status (6)

Country Link
US (1) US20050209300A1 (https=)
EP (1) EP1677794B1 (https=)
JP (1) JP4908215B2 (https=)
CA (1) CA2538759C (https=)
ES (1) ES2530972T3 (https=)
WO (1) WO2005026112A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20070105109A1 (en) * 2003-07-02 2007-05-10 Geesaman Bard J Sirt1 and genetic disorders
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
CA2540289A1 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Substituted indole derivatives
US20050250794A1 (en) * 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8143257B2 (en) * 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
AU2006218403A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20090022694A1 (en) * 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
EP1891949A1 (en) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Use of tricyclic indole derivatives for the treatment of muscular atrophy
WO2008019825A1 (en) * 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
EP2142669A4 (en) * 2007-04-12 2012-01-04 Harvard College SIRTUIN-BASED METHODS AND COMPOSITIONS FOR TREATING B-CATENIN ASSOCIATED SUFFERINGS
WO2009099643A1 (en) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Use of sirt1 activators or inhibitors to modulate an immune response
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
US20140249193A1 (en) * 2011-04-12 2014-09-04 The Regents Of The University Of California Modulators of mitochondrial protein import
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
WO2016040505A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
JP2017537940A (ja) 2014-12-10 2017-12-21 マサチューセッツ インスティテュート オブ テクノロジー 増殖性疾患の処置に有用な融合１，３−アゾール誘導体
CN109071456A (zh) 2016-02-16 2018-12-21 麻省理工学院 作为myc调节剂的max结合剂及其用途
PY2438443A (es) 2023-05-16 2025-06-18 Aop Orphan Ip Ag Nuevos polimorfos de (s)-6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida en forma cristalina
PY2438446A (es) 2023-05-16 2025-06-18 Aop Orphan Ip Ag Preparación de (s)-6-cloro-2,3,4,9- tetrahidro-1h-carbazol-1-carboxamida en forma enantioméricamente enriquecida mediante proceso de resolución

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769298A (en) * 1971-04-02 1973-10-30 Pfizer Substituted aminomethylcarbazoles
BE793493A (fr) * 1971-12-30 1973-06-29 Hoffmann La Roche Composes tricycliques
DE2226703A1 (de) * 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
DE2431292A1 (de) * 1974-06-27 1976-01-15 Schering Ag Neue carbazol-derivate
BG25793A3 (bg) * 1973-07-18 1978-12-12 Schering Aktiengesellschaft Метод за получаване на карбазолови деривати
MX9700696A (es) * 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
US6045398A (en) * 1995-07-10 2000-04-04 International Business Machines Corporation Battery accepting unit and battery pack
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US7241743B2 (en) * 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
NZ533430A (en) * 2001-12-14 2005-12-23 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
EP1513522A2 (en) * 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor

Also Published As

Publication number Publication date
JP2007505148A (ja) 2007-03-08
WO2005026112A3 (en) 2005-11-24
US20050209300A1 (en) 2005-09-22
JP4908215B2 (ja) 2012-04-04
EP1677794A4 (en) 2010-05-19
EP1677794B1 (en) 2014-12-03
ES2530972T3 (es) 2015-03-09
EP1677794A2 (en) 2006-07-12
WO2005026112A2 (en) 2005-03-24
CA2538759A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
US8486990B2 (en) SirT inhibitors that bind to NAD
CA2538759C (en) Substituted heterocyclic compounds as sirtuin inhitibitors
US20050250794A1 (en) Methods of treating a disorder
JP5747142B2 (ja) Ｄｙｒｋを阻害する化合物を含有する医薬組成物
WO2009033281A1 (en) Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
US20080214800A1 (en) Sirt inhibitors that bind to nad
CA2443031A1 (en) Use of selective cox-2 inhibitors for the treatment of urinary incontinence
US9567347B2 (en) Use of small molecule inhibitors targeting the interaction between RAC GTPase and p67(phox)
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
US6495586B2 (en) Scytonemin and methods of using thereof
JP2000500490A (ja) 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド
CN101035527A (zh) 治疗疾病的方法
US9457016B2 (en) Methods for treating polycystic kidney disease
CA3102598C (en) Inhibitors of sarm1
Shyamsivappan et al. Novel Thiadiazoline Spiro Quinoline Analogues Induced Cell Death In Mcf-7 Cells Via G2/M Phase Cell Cycle Arrest
US6495588B2 (en) Scytonemin and methods of using thereof
CN119923380A (zh) N-取代苯烷基胺及其作为治疗剂的应用

Legal Events

Date Code Title Description
EEER Examination request